BR112017005730A8 - Predição de evento de risco cardiovascular e usos da mesma - Google Patents

Predição de evento de risco cardiovascular e usos da mesma

Info

Publication number
BR112017005730A8
BR112017005730A8 BR112017005730A BR112017005730A BR112017005730A8 BR 112017005730 A8 BR112017005730 A8 BR 112017005730A8 BR 112017005730 A BR112017005730 A BR 112017005730A BR 112017005730 A BR112017005730 A BR 112017005730A BR 112017005730 A8 BR112017005730 A8 BR 112017005730A8
Authority
BR
Brazil
Prior art keywords
methods
prediction
gdf11
alpha
cardiovascular risk
Prior art date
Application number
BR112017005730A
Other languages
English (en)
Other versions
BR112017005730A2 (pt
BR112017005730B1 (pt
Inventor
Sterling David
Kato Shintaro
N Brody Edward
A Williams Stephen
Original Assignee
Somalogic Inc
Somalogic Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc, Somalogic Operating Co Inc filed Critical Somalogic Inc
Publication of BR112017005730A2 publication Critical patent/BR112017005730A2/pt
Publication of BR112017005730A8 publication Critical patent/BR112017005730A8/pt
Publication of BR112017005730B1 publication Critical patent/BR112017005730B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q40/00—Finance; Insurance; Tax strategies; Processing of corporate or income taxes
    • G06Q40/08—Insurance
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/205—Aptamer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Theoretical Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Business, Economics & Management (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)

Abstract

Métodos e métodos de computador usados para avaliar um indivíduo para a predição de risco de desenvolver um Evento Cardiovascular ao longo de um período de 1 a 5 anos são fornecidos. Os métodos empregam pelo menos dois biomarcadores selecionados de MMP12, agiopoietina-2, complemento C7, troponina cardíaca I, proteína 4 relativa a anfioproteína, CCL18/PARC, complexo alfa-1-antiquimotripsina, GDF11 e alfa-2-antiplasmina ou GDF11 em combinação com FSTL3. Os métodos são particularmente úteis na predição de eventos CV em pacientes que sofrem de doença cardíaca coronariana (CHD).
BR112017005730-1A 2014-09-26 2014-11-03 Método para triagem de um indivíduo quanto ao risco de um evento cardiovascular ou para predizer a probabilidade que um indivíduo tenha tal evento BR112017005730B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462055984P 2014-09-26 2014-09-26
US62/055,984 2014-09-26
PCT/US2014/063714 WO2016048388A1 (en) 2014-09-26 2014-11-03 Cardiovascular risk event prediction and uses thereof

Publications (3)

Publication Number Publication Date
BR112017005730A2 BR112017005730A2 (pt) 2017-12-19
BR112017005730A8 true BR112017005730A8 (pt) 2022-10-18
BR112017005730B1 BR112017005730B1 (pt) 2023-12-12

Family

ID=51982763

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017005730-1A BR112017005730B1 (pt) 2014-09-26 2014-11-03 Método para triagem de um indivíduo quanto ao risco de um evento cardiovascular ou para predizer a probabilidade que um indivíduo tenha tal evento

Country Status (9)

Country Link
US (2) US10670611B2 (pt)
EP (1) EP3198023B1 (pt)
JP (3) JP2017530356A (pt)
KR (1) KR102328327B1 (pt)
AU (1) AU2014407088B2 (pt)
BR (1) BR112017005730B1 (pt)
CA (2) CA2961340C (pt)
ES (1) ES2792227T3 (pt)
WO (1) WO2016048388A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080228699A1 (en) 2007-03-16 2008-09-18 Expanse Networks, Inc. Creation of Attribute Combination Databases
US8108406B2 (en) 2008-12-30 2012-01-31 Expanse Networks, Inc. Pangenetic web user behavior prediction system
EP2370929A4 (en) 2008-12-31 2016-11-23 23Andme Inc LOOKING FOR PARENTS IN A DATABASE
WO2015156125A1 (ja) * 2014-04-11 2015-10-15 株式会社 日立メディコ 医用画像撮影装置及び医用画像撮影方法
CN118522390A (zh) * 2016-04-01 2024-08-20 20/20基因系统股份有限公司 帮助区别良性和恶性放射线照相明显肺结节的方法和组合物
WO2017214684A1 (en) * 2016-06-17 2017-12-21 Adelaide Research & Innovation Pty Ltd Methods and products for identifying conditions associated with cardiac fibrotic remodelling
KR102322258B1 (ko) 2017-05-19 2021-11-04 현대자동차 주식회사 마이크로폰 및 그 제조 방법
US11079394B2 (en) * 2017-07-25 2021-08-03 Vanderbilt University Detection of angiopoietin-2 and thrombospondin-2 in connection with diagnosing acute heart failure
WO2019074491A1 (en) * 2017-10-10 2019-04-18 Flagship Biosciences, Inc. PATIENT STRATIFICATION METHOD USING IMAGE ANALYSIS PARAMETER DELIVERY FUNCTIONS
US10825564B1 (en) * 2017-12-11 2020-11-03 State Farm Mutual Automobile Insurance Company Biometric characteristic application using audio/video analysis
US10503970B1 (en) 2017-12-11 2019-12-10 State Farm Mutual Automobile Insurance Company Method and system for identifying biometric characteristics using machine learning techniques
JP7058331B2 (ja) * 2017-12-13 2022-04-21 エフ．ホフマン－ラ ロシュ アーゲー 脳卒中の予測のための循環アンジオポエチン－２（Ａｎｇ－２）およびインスリン様増殖因子結合タンパク質７（ＩＧＦＢＰ７）
US11317872B2 (en) * 2017-12-15 2022-05-03 Mayo Foundation For Medical Education And Research Predicting transient ischemic events using ECG data
US20190295727A1 (en) * 2018-03-23 2019-09-26 American Heart Association, Inc. System and Method for Assessing Heart Health and Communicating the Assessment to a Patient
CN113474358A (zh) * 2019-02-08 2021-10-01 日本电气株式会社 人t细胞白血病病毒1型(htlv-1)相关疾病的诊断方法
TWI741914B (zh) * 2019-03-06 2021-10-01 國立清華大學 檢測心血管疾病的檢驗套組及心血管疾病相關生物標記的濃度檢測方法
TWI741915B (zh) * 2019-03-06 2021-10-01 國立清華大學 檢測心血管疾病的檢驗套組及心血管疾病相關生物標記的濃度檢測方法
TWI716827B (zh) * 2019-03-06 2021-01-21 國立清華大學 檢測心血管疾病的檢驗套組及心血管疾病相關生物標記的濃度檢測方法
CN110068676A (zh) * 2019-03-22 2019-07-30 同济大学 分泌蛋白Serpin A3在预测心肌损伤诊断试剂中的应用
JP7215682B2 (ja) * 2019-09-09 2023-01-31 ａｉｗｅｌｌ株式会社 情報処理システムおよびプログラム
CN110838339B (zh) * 2019-09-23 2023-05-05 广东工业大学 邻苯二甲酸酯对斑马鱼毒性效应的预测方法、设备及介质
EP4044099A4 (en) * 2019-10-10 2022-11-16 Sony Group Corporation DISPLAY CONTROL DEVICE, DISPLAY CONTROL METHOD AND PROGRAM
US10902955B1 (en) * 2020-05-01 2021-01-26 Georgetown University Detecting COVID-19 using surrogates
US20230220472A1 (en) * 2020-05-28 2023-07-13 The Regents Of The University Of Michigan Deterimining risk of spontaneous coronary artery dissection and myocardial infarction and sysems and methods of use thereof
US11416776B2 (en) * 2020-08-24 2022-08-16 Kpn Innovations, Llc. Method of and system for identifying and enumerating cross-body degradations
US20230393146A1 (en) * 2020-10-20 2023-12-07 Somalogic Operating Co., Inc. Cardiovascular Event Risk Prediction
CN117099000A (zh) * 2021-03-08 2023-11-21 赛诺菲 心血管疾病
WO2023086746A1 (en) * 2021-11-11 2023-05-19 Beckman Coulter, Inc. Assessment of risk for major adverse cardiac event
CN114445445B (zh) * 2022-04-08 2022-07-01 广东欧谱曼迪科技有限公司 Ct图像的动脉分割方法、装置、电子设备及存储介质
CN117594131B (zh) * 2024-01-17 2024-04-16 北京市心肺血管疾病研究所 用于鉴别或辅助鉴别急性胸痛类型的装置及其应用
CN118152994B (zh) * 2024-05-11 2024-07-16 四川开物信息技术有限公司 一种安全因素影响计算方法

Family Cites Families (250)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642284A (en) 1983-06-13 1987-02-10 Scripps Clinic And Research Foundation Method and system for detection of complement pathway activation
JPS60192263A (ja) 1984-03-13 1985-09-30 Teijin Ltd 免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法
US5582862A (en) 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US6287793B1 (en) 1988-08-19 2001-09-11 Elan Pharmaceuticals, Inc. Diagnostic methods for alzheimer's disease
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5475096A (en) 1990-06-11 1995-12-12 University Research Corporation Nucleic acid ligands
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
AT398004B (de) 1992-04-14 1994-08-25 Berbi Gmbh Verfahren zur bestimmung von plasmin-alpha2- antiplasmin-komplexen unter verwendung eines komplexspezifischen monoklonalen antikörpers
EP0574599A1 (en) 1992-06-13 1993-12-22 BEHRINGWERKE Aktiengesellschaft Process for the detection of complexed cathepsin G and alpha-1-antichymotrypsin
ATE184400T1 (de) 1993-05-17 1999-09-15 Fortron Bioscience Inc Assay für troponin i aus dem herzmuskel
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
CA2194660C (en) 1994-07-08 2009-09-29 Se-Jin Lee Growth differentiation factor-11
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
FR2729759A1 (fr) 1995-01-19 1996-07-26 Pasteur Sanofi Diagnostics Procede de dosage ultrasensible de la troponine i cardiaque
WO1996031598A1 (en) 1995-04-06 1996-10-10 Regeneron Pharmaceuticals, Inc. Tie-2 ligands, methods of making and uses thereof
US6627404B1 (en) 1995-04-18 2003-09-30 Biosite, Inc. Methods for improving the recovery of troponin I and T in membranes, filters and vessels
US5795725A (en) 1995-04-18 1998-08-18 Biosite Diagnostics Incorporated Methods for the assay of troponin I and T and selection of antibodies for use in immunoassays
DE69633780T3 (de) 1995-04-18 2011-05-05 Biosite Incorporated, San Diego Verfahren zum assay von troponin i und t und komplexen von troponin i und t und auswahl von antikörpern zur verwendung in immunoassays
US6991907B1 (en) 1995-04-18 2006-01-31 Biosite, Inc. Methods for the assay of troponin I and T and complexes of troponin I and T and selection of antibodies for use in immunoassays
FI104857B (fi) 1996-01-15 2000-04-14 Hytest Oy Sydänlihaksen soluvaurioiden asteen mittaus immunokemiallisella menetelmällä sisältäen menetelmään soveliaat vasta-aineet
US7285418B2 (en) 1996-06-25 2007-10-23 Hytest Ltd. Method and kit for the diagnosis of troponin I
AU3178697A (en) 1996-06-25 1998-01-14 Oy Aboatech Ab Method and kit for the diagnosis of troponin i
US6265564B1 (en) 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
US6156521A (en) 1997-12-19 2000-12-05 Biosite Diagnostics, Inc. Methods for the recovery and measurement of troponin complexes
WO1998029726A2 (en) 1996-12-27 1998-07-09 Coulter International Corp. Method of detecting and determining the concentration of total troponin i in a biological sample
US6670196B1 (en) 1997-05-14 2003-12-30 Biosite, Inc. Rapid evaluation of the ratio of biological molecules
US7384751B1 (en) 1997-07-16 2008-06-10 Queen's University At Kingston Methods of diagnosing muscle damage
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
AU6117099A (en) 1998-10-21 2000-05-08 Spectral Diagnostics Inc. Cardiac troponin i polypeptide fragments and uses in diagnostics
US20020110523A1 (en) 1999-03-23 2002-08-15 Cornelis Kluft Methods for screening or monitoring the risk of cardiovascular disease relating to sex steroid compound or composition intake and methods for screening sex steroid compound
US20030077668A1 (en) 1999-07-22 2003-04-24 Ikagaku Co., Ltd. Method for arteriosclerosis diagnosis
US7618782B1 (en) 1999-10-18 2009-11-17 Queen's University At Kingston Methods of diagnosing muscle damage
US20050272055A1 (en) 2000-02-01 2005-12-08 Rina Das Method of treating lethal shock induced by toxic agents and diagnosing exposure to toxic agents by measuring distinct pattern in the levels of expression of specific genes
US20030040505A1 (en) 2000-03-31 2003-02-27 The Regents Of The University Of California Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions
AUPR005600A0 (en) 2000-09-12 2000-10-05 University Of Sydney, The Diagnostic assay
AU2001296305B2 (en) 2000-09-26 2007-12-06 Duke University RNA aptamers and methods for identifying the same
WO2002063302A1 (en) 2001-02-07 2002-08-15 Immunomatrix Inc. A method for reducing heparin interference in diagnostic tests for cardiac troponin
US7632647B2 (en) 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20030199000A1 (en) 2001-08-20 2003-10-23 Valkirs Gunars E. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20040203083A1 (en) 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
US7524635B2 (en) 2003-04-17 2009-04-28 Biosite Incorporated Methods and compositions for measuring natriuretic peptides and uses thereof
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
DE60235416D1 (de) 2001-05-04 2010-04-01 Biosite Inc Diagnostische Marker der akuten koronaren Syndrome und ihre Verwendungen
US20020197741A1 (en) 2001-05-11 2002-12-26 Sabucedo Albert J. Method of determining time of death
EP2070939B1 (en) 2001-05-25 2014-04-02 Duke University Modulators of pharmacological agents
US20050026165A1 (en) 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
US20030003503A1 (en) 2001-06-29 2003-01-02 Tsai Tenlin S. Enhancing sensitivity and equimolar detection through modifications of the reaction environment
JP2005512021A (ja) 2001-07-09 2005-04-28 アリゾナ ボード オブ リージェンツ 生物学的プロセスをモニターするための親和性バイオセンサー
US7608406B2 (en) 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US6461828B1 (en) 2001-09-04 2002-10-08 Syn X Pharma Conjunctive analysis of biological marker expression for diagnosing organ failure
CA2507024A1 (en) 2001-11-27 2003-06-05 Diagenics International Corporation Immunoassay and kit for an early and simultaneous detection of biochemical markers in a patient's sample
US7371582B2 (en) 2002-01-23 2008-05-13 Boditechmed Inc. Lateral flow quantitative assay method and strip and laser-induced fluorescence detection device therefor
DE10211818B4 (de) 2002-03-16 2006-07-06 peS Gesellschaft für medizinische Diagnose-Systeme mbH Verfahren zur quantitativen Bestimmung mehrerer Analyten
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
EP1572937B1 (en) 2002-04-09 2012-02-08 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
HUE039881T2 (hu) 2002-05-09 2019-02-28 Brigham & Womens Hospital Inc 1L1RL-1, mint egy kardiovaszkuláris betegség-marker
AU2003268905A1 (en) 2002-05-21 2003-12-02 Mtm Laboratories Ag G - protein coupled receptor marker molecules associated with colorectal lesions
EP1530723A1 (en) 2002-07-03 2005-05-18 Spinelix 3d microarray
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
AU2003299933B2 (en) 2002-10-09 2010-06-24 Luoxis Diagnostics, Inc. Diagnosis and monitoring of inflammation, ischemia and appendicitis
US7135329B2 (en) 2002-11-18 2006-11-14 Princeton Biomeditech Corporation Immunoassay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients
EP1620567A1 (en) 2003-04-15 2006-02-01 Hans-Jürgen Thiesen Method for diagnosing rheumatoid arthritis or osteoarthritis
FI20030652A0 (fi) 2003-04-30 2003-04-30 Susann Eriksson Parannettu immunomääritys
US7659062B2 (en) 2003-06-03 2010-02-09 The Board of Trustee of the University of Arkansas System Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
US7927795B2 (en) 2003-06-09 2011-04-19 Board Of Trustees Of The University Of Arkansas Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium
ES2369667T3 (es) 2003-07-17 2011-12-02 Pacific Edge Limited Marcadores para la detección del cáncer gástrico.
US20050130193A1 (en) 2003-09-10 2005-06-16 Luxon Bruce A. Methods for detecting, diagnosing and treating human renal cell carcinoma
US20050181386A1 (en) 2003-09-23 2005-08-18 Cornelius Diamond Diagnostic markers of cardiovascular illness and methods of use thereof
US20080010024A1 (en) 2003-09-23 2008-01-10 Prediction Sciences Llp Cellular fibronectin as a diagnostic marker in cardiovascular disease and methods of use thereof
US7392140B2 (en) 2003-09-23 2008-06-24 Prediction Sciences, Llc Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof
US7634360B2 (en) 2003-09-23 2009-12-15 Prediction Sciences, LL Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof
EP1673465A4 (en) 2003-09-29 2008-04-30 Biosite Inc PROCESS AND COMPOSITIONS FOR SEPSIS DIAGNOSIS
US20050148029A1 (en) 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
DE10349124A1 (de) 2003-10-22 2005-05-19 Roche Diagnostics Gmbh Differenzialdiagnostik mit Hepcidin
US20050239706A1 (en) 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
EP1530047A1 (en) * 2003-11-07 2005-05-11 Roche Diagnostics GmbH Proximal markers of arterial thrombosis and inflammation for risk stratification of coronary heart disease
CA2546461A1 (en) 2003-11-19 2005-06-09 Satoris, Inc. Methods for diagnosis, stratification, and monitoring of alzheimer`s disease
US20050164409A1 (en) 2003-12-10 2005-07-28 Kiernan Urban A. Method and apparatus for mass spectrometric immunoassay analysis of specific biological fluid proteins
US8932808B1 (en) 2004-01-21 2015-01-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining a graft tolerant phenotype in a subject
CA2557438C (en) 2004-02-19 2017-01-17 Yale University Identification of cancer protein biomarkers using proteomic techniques
ES2550614T3 (es) 2004-04-09 2015-11-11 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
WO2005110489A2 (en) 2004-04-13 2005-11-24 (Osi) Eyetech, Inc. Nucleic acid aptamers conjugated to high molecular weight steric groups
WO2005113798A2 (en) 2004-04-15 2005-12-01 University Of Florida Research Foundation, Inc. Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining
ES2353311T3 (es) 2004-05-11 2011-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Diagnóstico de enfermedades o afecciones inflamatorias para la medición de componentes del complemento sobre la superficie de glóbulos blancos.
US20060039863A1 (en) 2004-07-22 2006-02-23 Michael Schirner Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
US20060105419A1 (en) 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
US20080090759A1 (en) 2004-08-30 2008-04-17 Robert Kokenyesi Methods and kits for predicting risk for preterm labor
US20060134698A1 (en) 2004-12-20 2006-06-22 Evanston Northwestern Healthcare Research Institute Methods for treating cardiac disease by modifying an N-terminal domain of troponin I
WO2006069073A2 (en) 2004-12-20 2006-06-29 The General Hospital Corporation Use of angiopoietins in anti-tumor therapy
JP4734654B2 (ja) 2004-12-27 2011-07-27 国立大学法人 岡山大学 妊娠中毒症の検査方法
US8178505B2 (en) 2005-01-05 2012-05-15 Sloan-Kettering Institute For Cancer Research Method of predicting and reducing risk of metastasis of breast cancer to lung
US20060199280A1 (en) 2005-03-03 2006-09-07 David Bar-Or Quantification of proteins
US20090054741A1 (en) 2005-03-29 2009-02-26 Inverness Medical Switzerland Gmbh Device and method of monitoring a patient
EP3578985B1 (en) 2005-05-05 2021-01-13 Drexel University Diagnosis of liver pathology through assessment of protein glycosylation
GB0509305D0 (en) 2005-05-06 2005-06-15 Randox Lab Ltd Method
US20060275849A1 (en) 2005-06-07 2006-12-07 Beckman Coulter, Inc. Monoclonal antibody reagents
CN101194027B (zh) 2005-06-08 2012-10-24 日立化成研究中心公司 用于基于瘤细胞及受刺激的白细胞内mRNA表达谱而预测对肿瘤疾病的免疫应答的方法
WO2006135781A2 (en) 2005-06-09 2006-12-21 Biosite, Inc. Methods and compositions for the diagnosis of venous thromboembolic disease
US20070099239A1 (en) 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
JP4891317B2 (ja) 2005-06-28 2012-03-07 ズィービーエックス・コーポレーション 膜アレイ及び分析用装置
US20070218498A1 (en) 2005-08-30 2007-09-20 Buechler Kenneth F Use of soluble FLT-1 and its fragments in cardiovascular conditions
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
AU2006299417A1 (en) 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in Systemic Inflammatory Response Syndromes
US7947437B2 (en) 2005-10-17 2011-05-24 Sword Diagnostics, Inc. Methods for detecting organisms and enzymatic reactions using raman spectroscopy
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US20100267025A1 (en) 2005-11-10 2010-10-21 Robert Peter Young Methods and compositions for the assessment of cardiovascular function and disorders
US7908090B2 (en) 2005-11-30 2011-03-15 The Board Of Trustees Of The Leland Stanford Junior University Signatures for human aging
US20140273007A1 (en) 2013-03-12 2014-09-18 Dr. Susan Love Research Foundation Devices and methods for screening nipple aspirate for markers indicative of risk of developing breast cancer
US20070134814A1 (en) 2005-12-09 2007-06-14 Kajander E O Methods and compositions for the detection of calcifying nano-particles, identification and quantification of associated proteins thereon, and correlation to disease
WO2007070021A1 (en) 2005-12-09 2007-06-21 Nanobac Pharmaceuticals Incorporated Detection of calcifying nano-particles, and associated proteins thereon
US7790463B2 (en) 2006-02-02 2010-09-07 Yale University Methods of determining whether a pregnant woman is at risk of developing preeclampsia
ES2562423T3 (es) 2006-03-08 2016-03-04 Archemix Llc Aptámeros de unión a complemento y agentes anti-C5 útiles para el tratamiento de trastornos oculares
EP2005168A4 (en) 2006-03-09 2009-05-20 Biosite Inc METHODS AND COMPOSITIONS FOR DIAGNOSING DISEASES OF AORTA
WO2007109307A2 (en) 2006-03-20 2007-09-27 Curagen Corporation Antibodies directed to angiopoietin-like protein 4 and uses thereof
AU2007313488A1 (en) 2006-04-04 2008-04-24 Singulex, Inc. Methods and compositions for highly sensitive analysis of markers and detection of molecules
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
ES2351623T3 (es) 2006-04-24 2011-02-08 Critical Care Diagnostics, Inc. Predicción de la mortalidad y detección de una enfermedad grave.
US20100055730A1 (en) 2006-05-05 2010-03-04 Anny Usheva-Simidjiyska Methods for the Diagnosis and Treatment of Female Infertility Using Molecular Markers
EP2021512A4 (en) 2006-05-08 2009-08-05 Tethys Bioscience Inc SYSTEMS AND METHODS FOR DEVELOPING DIAGNOSTIC TESTS BASED ON BIOMARKER INFORMATION FROM SURGICAL CLINICAL SAMPLES
US20080118924A1 (en) 2006-05-26 2008-05-22 Buechler Kenneth F Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases
MX2009001079A (es) 2006-07-28 2009-02-10 Adlyfe Inc Sondas de peptido para diagnosis y terapeutica.
EP1887361A1 (en) 2006-08-07 2008-02-13 Bio-Rad Pasteur Method for the prediction of vascular events
ES2457243T3 (es) 2006-09-08 2014-04-25 The Chancellor, Masters And Scholars Of The University Of Oxford Diagnóstico clínico de una fibrosis hepática utilizando APOL1 de suero humano como biomarcador
EP2074223A4 (en) 2006-09-15 2010-03-10 Foldrx Pharmaceuticals Inc TEST PROCEDURE FOR THE DETECTION OF PROTEINS IN THE NATIVE CONDITION AND FOR THE IDENTIFICATION OF THE STABILITY OF PROTEINS IN THE NATIVE CONDITION MODULATING COMPOUNDS
CN101627129B (zh) 2006-10-06 2014-07-02 雀巢产品技术援助有限公司 用于测量生理健康的生物介体的组合物和多路检验
US20080305512A1 (en) 2006-10-26 2008-12-11 Mattingly Phillip G Assay for cardiac troponin autoantibodies
US7776605B2 (en) 2006-10-26 2010-08-17 Abbott Laboratories Assay for cardiac troponin autoantibodies
JP2010513277A (ja) * 2006-12-13 2010-04-30 ギリード・サイエンシズ・インコーポレーテッド ＣＯＰＤおよび慢性気管支炎の治療のためのムスカリン受容体アンタゴニストおよびβ−アゴニストの共通プロドラッグとしてのモノホスフェート
RU2473555C2 (ru) * 2006-12-19 2013-01-27 ДжинГоу, Инк. Новые способы функционального анализа большого количества экспериментальных данных и групп генов, идентифицированных из указанных данных
CA2673092A1 (en) 2006-12-19 2008-06-26 Synergenz Bioscience Limited Methods and compositions for the assessment of cardiovascular function and disorders
WO2008074330A1 (en) 2006-12-20 2008-06-26 Antibodyshop A/S Assessment of patients with sepsis to determine a requirement for therapeutic intervention with an antiinflammatory and/or anticoagulatory agent
US20080300797A1 (en) 2006-12-22 2008-12-04 Aviir, Inc. Two biomarkers for diagnosis and monitoring of atherosclerotic cardiovascular disease
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
WO2008131039A2 (en) 2007-04-16 2008-10-30 Board Of Regents, The University Of Texas System Cardibioindex/cardibioscore and utility of salivary proteome in cardiovascular diagnostics
US7901888B2 (en) 2007-05-09 2011-03-08 The Regents Of The University Of California Multigene diagnostic assay for malignant thyroid neoplasm
BRPI0810631A2 (pt) 2007-05-10 2017-05-09 Acorda Therapeutics Inc métodos para detecção de dano cardíaco
EP2069496A4 (en) 2007-07-17 2010-01-27 Somalogic Inc SELEX AND PHOTOSELEX ENHANCED
EP2019318A1 (en) 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
WO2010012509A1 (en) 2008-08-01 2010-02-04 Bio-Rad Pasteur Method for the in vitro diagnosis of stroke
WO2009036123A1 (en) 2007-09-11 2009-03-19 Cancer Prevention And Cure, Ltd. Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues
KR20100098697A (ko) 2007-12-13 2010-09-08 글락소 그룹 리미티드 폐 전달을 위한 조성물
GB0724735D0 (en) 2007-12-19 2008-01-30 Psynova Neurotech Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
US20090299155A1 (en) 2008-01-30 2009-12-03 Dexcom, Inc. Continuous cardiac marker sensor system
US20100016173A1 (en) 2008-01-30 2010-01-21 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
WO2009108073A1 (en) 2008-02-28 2009-09-03 Auckland Uniservices Limited Biomarkers for prediction of preeclampsia and/or cardiovascular disease
US20090234202A1 (en) 2008-03-05 2009-09-17 Goix Philippe J Method and compositions for highly sensitive detection of molecules
WO2009111033A2 (en) 2008-03-05 2009-09-11 Axela Inc. Detection of biomarkers and biomarker complexes
WO2009118185A1 (en) 2008-03-27 2009-10-01 Universitätsklinikum Heidelberg Peptides derived from cardial troponin i and their use as prognostic and diagnostic markers for heart failure
PT2269063E (pt) 2008-04-18 2013-11-27 Critical Care Diagnostics Inc Predição do risco de eventos cardíacos adversos maiores
FR2934767B1 (fr) 2008-08-06 2011-11-25 Assist Publ Hopitaux De Paris Nouveau procede de pronostic associe aux cas d'hemorragies post-partum.
WO2012006632A2 (en) 2010-07-09 2012-01-12 Somalogic, Inc. Lung cancer biomarkers and uses thereof
GB0818660D0 (en) 2008-10-10 2008-11-19 Cambridge Entpr Ltd Biomarkers
US20110295782A1 (en) 2008-10-15 2011-12-01 Alexander Stojadinovic Clinical Decision Model
CA2741087A1 (en) 2008-10-21 2010-04-29 Bayer Healthcare Llc Identification of signature genes associated with hepatocellular carcinoma
ES2579210T3 (es) 2008-10-24 2016-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) NGAL como biomarcador para la activación del receptor de mineralocorticoides
EP3913367A1 (en) 2008-12-30 2021-11-24 Children's Medical Center Corporation Method of predicting acute appendicitis
WO2010078443A1 (en) 2008-12-31 2010-07-08 Abbott Point Of Care Inc. Method and device for immunoassay using nucleotide conjugates
EP2411804B1 (en) 2009-01-30 2015-08-26 Bio-Rad Innovations Method for the in vitro diagnosis of stroke
US20100216256A1 (en) 2009-02-17 2010-08-26 Florida State University Research Foundation Nanobelt-based sensors and detection methods
CN102326081B (zh) 2009-02-24 2014-11-19 霍夫曼-拉罗奇有限公司 s-ErbB-3作为癌症标志物的应用
WO2010129302A1 (en) 2009-04-28 2010-11-11 Innovative Laboratory Technologies, Inc. Lateral-flow immuno-chromatographic assay devices
US8450069B2 (en) 2009-06-08 2013-05-28 Singulex, Inc. Highly sensitive biomarker panels
WO2010144553A2 (en) 2009-06-10 2010-12-16 Tufts Medical Center, Inc. Methods for diagnosing blood vessel reocclusion
WO2011017077A2 (en) 2009-07-27 2011-02-10 Trustees Of Boston University Nanochannel-based sensor system with controlled sensitivity
EP2467720A1 (en) 2009-08-20 2012-06-27 The Board of Regents of The University of Texas System Methods and compositions for diagnosis of acute myocardial infarction (ami)
US8501420B2 (en) 2009-08-31 2013-08-06 Abbott Laboratories Biomarkers for prediction of major adverse cardiac events and uses thereof
EP2480887B1 (en) 2009-09-23 2015-12-16 Koninklijke Philips N.V. Binding assay with multiple magnetically labelled tracer binding agents
US8846414B2 (en) 2009-09-29 2014-09-30 Advanced Liquid Logic, Inc. Detection of cardiac markers on a droplet actuator
US20120231472A1 (en) 2009-11-07 2012-09-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2013511732A (ja) 2009-11-24 2013-04-04 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼーション 神経障害の診断、診断補助および／またはその進行のモニタリングのための方法、キットおよび試薬
US8652788B2 (en) 2009-12-02 2014-02-18 Abbott Laboratories Assay for diagnosis of cardiac myocyte damage
US20110136141A1 (en) 2009-12-03 2011-06-09 Abbott Laboratories Peptide reagents and method for inhibiting autoantibody antigen binding
AU2010328019A1 (en) * 2009-12-09 2012-06-28 Aviir, Inc. Biomarker assay for diagnosis and classification of cardiovascular disease
BR112012015266A2 (pt) 2009-12-23 2017-10-10 Koninl Philips Electronics Nv dispositivo configurado para receber uma amostra e método para determinar a presença de um analito em uma amostra
CA2785592A1 (en) 2010-01-08 2011-07-14 Cavadis B.V. Determination of exosomel biomarkers for predicting cardiovascular events
US20130023473A1 (en) 2010-01-20 2013-01-24 Stephane Germain Methods and pharmaceutical composition for the preservation of vascular endothelial cell barrier integrity
EP2531622B1 (en) 2010-02-05 2016-04-06 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2536760A4 (en) 2010-02-17 2013-10-16 Univ Johns Hopkins NEW PHOSPHORYLATION OF CARDIAC TROPONIN I AS A MONITOR OF CARDIAC INJURY
EP2553117A1 (en) 2010-03-28 2013-02-06 Sword Diagnostics, Inc. Methods for detecting raman scattering using aromatic compounds comprising phosphate and at least one non-laser light source
EP2372364A1 (en) 2010-03-31 2011-10-05 Medizinische Hochschule Hannover Biomarker for pulmonary hypertension
US20110301053A1 (en) 2010-05-06 2011-12-08 Singulex, Inc. Methods for Diagnosing, Staging, Predicting Risk for Developing and Identifying Treatment Responders for Rheumatoid Arthritis
WO2011143574A2 (en) 2010-05-14 2011-11-17 The Trustees Of The University Of Pennsylvania Plasma biomarkers for diagnosis of alzheimer's disease
MX2013000220A (es) 2010-06-23 2013-03-22 Astute Medical Inc Metodos y composiciones para diagnóstico y pronóstico de lesión renal e insuficiencia renal.
US9918656B2 (en) 2010-06-25 2018-03-20 Massachusetts Institute Of Technology Implantable magnetic relaxation sensors and methods of measuring a sensor's cumulative exposure to a biomarker
ES2387292B1 (es) 2010-06-29 2013-10-30 Fundacio Institut De Recerca Hospital Universitari Vall D'hebron Combinacion de snps para determinar el riesgo de sufrir una enfermedad neurovascular
CN103097552B (zh) * 2010-07-14 2015-10-07 加利福尼亚大学董事会 用于诊断短暂性缺血发作的生物标志物
US20120142632A1 (en) 2010-08-04 2012-06-07 St. Vincent's Institute Of Medical Research Diagnostic and prognostic assay
CN103118785B (zh) 2010-08-05 2015-11-25 雅培医护站股份有限公司 使用易感磁微珠捕获的免疫测定方法和装置
WO2012019109A1 (en) 2010-08-05 2012-02-09 Abbott Point Of Care Inc. Oscillating immunoassay method and device
CN103299191B (zh) * 2010-08-13 2016-06-15 莫尔豪斯医学院 中风的生物标记
CN103080746B (zh) 2010-08-26 2015-07-15 弗·哈夫曼-拉罗切有限公司 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途
US20120077695A1 (en) 2010-09-27 2012-03-29 Somalogic, Inc. Mesothelioma Biomarkers and Uses Thereof
WO2012052757A1 (en) 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
US20120115175A1 (en) 2010-11-05 2012-05-10 Tufts Medical Center, Inc. Methods for diagnosing elevated right or left ventricular filling pressure
WO2012065176A2 (en) 2010-11-12 2012-05-18 The Johns Hopkins University Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease
EP2661626B1 (en) 2011-01-08 2016-06-01 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN103403554A (zh) 2011-02-03 2013-11-20 雅培制药有限公司 慢性心力衰竭的预后和诊断方法
US20140024046A1 (en) 2011-02-18 2014-01-23 Cavadis B.V. Exosomal Biomarkers for Cardiovasular Events
WO2012115885A1 (en) 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
US20140199781A1 (en) 2011-03-08 2014-07-17 Beth Israel Deaconess Medical Center, Inc. Non-invasive methods for diagnosing chronic organ transplant rejection
FI20115367A0 (fi) 2011-04-15 2011-04-15 Hytest Oy Menetelmä sydän- ja verisuonitapahtumien määrittämiseksi käyttämällä IGFBP-fragmentteja
JP2014514572A (ja) 2011-04-29 2014-06-19 キャンサー・プリヴェンション・アンド・キュア，リミテッド 分類システムおよびそのキットを使用した肺疾患の同定および診断方法
EP2532748B1 (en) 2011-06-07 2014-10-08 Postech Academy-industry Foundation DNA aptamer specifically binding to human cardiac troponin I
US9387236B2 (en) 2011-06-10 2016-07-12 Prothera Inc. Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases
JP6134316B2 (ja) 2011-07-18 2017-05-24 クリティカル ケア ダイアグノスティクス インコーポレイテッド 心臓血管疾患を治療する方法および運動療法の有効性を予測する方法
SG10201607346XA (en) 2011-08-08 2016-10-28 Univ Nanyang Tech Angiopoietin-like 4 and its use in modulating cell leakiness
CN103874770A (zh) 2011-08-08 2014-06-18 卡里斯生命科学卢森堡控股有限责任公司 生物标志物组合物和方法
US20140370502A1 (en) 2011-09-08 2014-12-18 Nexus Dx, Inc. Multilevel analyte assay
CA3074279C (en) 2011-09-30 2021-10-19 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
EP2594940A1 (en) 2011-11-16 2013-05-22 Koninklijke Philips Electronics N.V. Particle repulsion to enhance surface contact in magnetic particle immunoassays
EP2594942A1 (en) 2011-11-16 2013-05-22 Koninklijke Philips Electronics N.V. Long rigid spacers to enhance binding kinetics in immunoassays
KR101492696B1 (ko) 2011-12-09 2015-02-12 경북대학교 산학협력단 심근 트로포닌 ⅰ과 특이적으로 결합하는 폴리펩타이드 및 이의 용도
US8986530B2 (en) 2012-01-09 2015-03-24 Washington State University Sample analysis systems, devices, and associated methods of operation
US9140695B2 (en) 2012-01-18 2015-09-22 University Of Utah Research Foundation Methods for analysis of free and autoantibody-bound biomarkers and associated compositions, devices, and systems
WO2013127000A1 (en) 2012-02-27 2013-09-06 University Health Network (Uhn) Biomarkers for early determination of a critical or life threatening response to illness and monitoring response to treatment thereof
WO2013135830A1 (en) * 2012-03-14 2013-09-19 Ruprecht-Karls-Universität Heidelberg Epigenetic signatures as marker for cardiomyopathies and myocardial insufficiencies
ES2897573T3 (es) 2012-03-26 2022-03-01 Xcellcure Llc Dispositivo y procedimiento para la detección de analitos
WO2013152047A1 (en) 2012-04-02 2013-10-10 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of sepsis
CA2870810A1 (en) 2012-04-18 2013-10-24 The University Of British Columiba Biomarkers for recovered heart function
WO2013163345A1 (en) 2012-04-24 2013-10-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of stroke or other cerebral injury
US20150141273A1 (en) 2012-04-26 2015-05-21 Stichting Vu-Vumc Biomarkers
WO2013169890A1 (en) 2012-05-08 2013-11-14 Bg Medicine, Inc. Systems and methods for assessing disease risk, status, and prognosis
ITMI20120865A1 (it) 2012-05-18 2013-11-19 Antonio Bertolotto Biomarcatori per patologie del sistema nervoso centrale
AU2013262515B2 (en) 2012-05-18 2018-03-15 Cardiac Pacemakers, Inc. Methods for treating or predicting risk of a ventricular tachyarrhythmia event
US9482616B2 (en) 2012-06-06 2016-11-01 Board of Regents of the Nevada System of Higher Education, on behalf the University of Nevada, Reno Methods, kits and systems for signal amplification for bioassays using zinc nanoparticles
US10175250B2 (en) 2012-06-11 2019-01-08 Gabriela Venturini Da Silva Nitrated cardiac troponin I as a biomarker of cardiac ischemia
WO2014004889A2 (en) 2012-06-27 2014-01-03 Musc Foundation For Research Development Plasma analytes predict diagnosis and prognosis of thoracic aortic aneurysm
CN104737023B (zh) 2012-08-16 2017-07-28 重症监护诊断股份有限公司 预测患高血压风险的方法
US20140120551A1 (en) 2012-10-29 2014-05-01 Academia Sinica Methods of diagnosing, predicting and treating cardiovascular disease
EP2932696A4 (en) 2012-12-12 2016-08-24 Green Domain Design Llc ASSAY DEVICE
US20140206632A1 (en) 2013-01-22 2014-07-24 Singulex, Inc. Endothelin in the Diagnosis of Cardiac Disease
WO2014122467A1 (en) 2013-02-06 2014-08-14 Loxbridge Research Llp Systems and methods for early disease detection and real-time disease monitoring
WO2014127265A1 (en) 2013-02-14 2014-08-21 Singulex, Inc. Non-invasive methods to determine vulnerable plaque burden in subjects
WO2014144605A1 (en) 2013-03-15 2014-09-18 Myriad Genetics, Inc. Biomarkers for major depressive disorder
WO2014187884A2 (en) 2013-05-22 2014-11-27 Comprehensive Biomarker Center Gmbh Mirnas as non-invasive biomarkers for heart failure
WO2015034897A1 (en) * 2013-09-03 2015-03-12 Mayo Foundation For Medical Education And Research Reducing the risk of major adverse cardiac events
GB201315943D0 (en) 2013-09-06 2013-10-23 Randox Lab Ltd Risk stratification of suspected ami patients
GB2518221A (en) 2013-09-16 2015-03-18 Sergej Michailovic Kiprijanov Tetravalent antigen-binding protein molecule
EP3693738A1 (en) 2013-09-20 2020-08-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
EP3052936A4 (en) 2013-09-23 2017-05-24 Assaypro, LLC Immunoassays using over-labeled fluorescent probes
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
US10017566B2 (en) * 2013-11-12 2018-07-10 The Brigham And Women's Hospital, Inc. Growth differentiation factor (GDF) for treatment of diastolic heart failure
US20160305959A1 (en) * 2013-11-14 2016-10-20 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN Detection of atherosclerotic cardiovascular disease risk
WO2015085368A1 (en) 2013-12-10 2015-06-18 The University Of Queensland Kits and methods for the diagnosis, treatment, prevention and monitoring of diabetes

Also Published As

Publication number Publication date
BR112017005730A2 (pt) 2017-12-19
AU2014407088B2 (en) 2021-09-23
KR20170062453A (ko) 2017-06-07
JP2017530356A (ja) 2017-10-12
CA3103560A1 (en) 2016-03-31
JP2022008847A (ja) 2022-01-14
BR112017005730B1 (pt) 2023-12-12
EP3198023B1 (en) 2020-04-22
KR102328327B1 (ko) 2021-11-22
US10670611B2 (en) 2020-06-02
ES2792227T3 (es) 2020-11-10
AU2014407088A1 (en) 2017-03-16
EP3198023A1 (en) 2017-08-02
JP2019207249A (ja) 2019-12-05
JP7270696B2 (ja) 2023-05-10
CA3103560C (en) 2023-01-17
US20160091499A1 (en) 2016-03-31
WO2016048388A1 (en) 2016-03-31
US20180188267A1 (en) 2018-07-05
CA2961340A1 (en) 2016-03-31
JP6956762B2 (ja) 2021-11-02
CA2961340C (en) 2023-10-17

Similar Documents

Publication Publication Date Title
BR112017005730A8 (pt) Predição de evento de risco cardiovascular e usos da mesma
BR112018070971A2 (pt) métodos e kits para a diagnose e estratificação de risco de pacientes com isquemia
Feigin et al. New strategy to reduce the global burden of stroke
BR112017014419A2 (pt) diagnose e tratamento de diabetes incipiente
BR112018002848A2 (pt) método, aparelho, mídia de armazenamento não transitório, programa de computador, kit para medir níveis de expressão de seis ou mais genes-alvo da via de sinalização celular
BR112018015698A2 (pt) ?métodos diagnósticos e prognósticos para doenças cardiovasculares e eventos?
BR112018071583A2 (pt) métodos para determinar dpp3 e métodos terapêuticos
BR112019004075A2 (pt) métodos para diagnosticar um indivíduo com suspeita de endometriose, para detectar mirna, para diagnosticar um indivíduo que apresenta sintomas de endometriose ou com suspeita de endometriose, para tratar um indivíduo com endometriose, para diagnosticar e tratar um indivíduo com suspeita de endometriose, para diagnosticar endometriose em um indivíduo, para diagnosticar ou prover um prognóstico para endometriose em um indivíduo e para monitorar uma resposta a um tratamento de endometriose em um indivíduo, e, kit.
BR112015022556A2 (pt) estruturas de sola e artigos de calçado tendo palmilhas leves com elementos de proteção
BR112016007119A2 (pt) domínios de falha em hardware moderno
WO2015176066A3 (en) Lpa-associated protein and rna expression
BR112016028534A2 (pt) ceramidas e seu uso em diagnosticar cvd
BR112017022320A2 (pt) métodos para tratamento de câncer de pulmão
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
BR112015004800A2 (pt) método e aparelho para examinar ovos
BR112018008799A2 (pt) método de prognóstico
BR112017006315A2 (pt) agente terapêutico, uso de um agente terapêutico, métodos in vitro para determinar se um sujeito com melanoma tem um risco maior de desenvolver metástase, de determinação de um regime de tratamento para um sujeito que sofre de melanoma, de tratamento de um sujeito que sofre de melanoma, ensaio in vitro para predizer o risco aumentado de metástase e kits
BR112018011224A2 (pt) processo de avaliação do risco de complicações nos pacientes que apresentam uma síndrome da resposta inflamatória sistêmica (sirs)
BR112019007096A2 (pt) método para a detecção de apolipoproteína e4
BR112017008805A2 (pt) tratamento de córnea usando laminina
BR112016017926A2 (pt) ensaio para detectar periostina humana
MX2020006388A (es) Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea.
BR112017003876A2 (pt) molécula antitrombótica, uso de uma molécula antitrombótica, e, métodos para fabricação de uma molécula antitrombótica e para tratamento de uma doença ou condição.
PL406989A1 (pl) Profil mikro RNA we krwi jako test wykrywania raka płuca
RU2014113841A (ru) Способ ранней диагностики эндогенной интоксикации

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: SOMALOGIC OPERATING CO., INC. (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/11/2014, OBSERVADAS AS CONDICOES LEGAIS